Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ6 | P48051 | 8/20 | 0.47 |
| ▸ | KCNJ5 | P48544 | 8/20 | 0.47 |
| ▸ | KCNJ3 | P48549 | 8/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521756 | 0.89 | KCNJ6 (0.48) | KCNJ6KCNJ5KCNJ3FGFR4MAPK14 | |
| SCHEMBL1521814 | 0.80 | MAPK14 (0.52) | MAPK14MAPK12MAPK13MAPK11BRAF | |
| SCHEMBL1521813 | 0.80 | MAPK14 (0.46) | FGFR4MAPK14MAPK12MAPK13MAPK11 | |
| SCHEMBL1521734 | 0.79 | MAPK14 (0.51) | FGFR4MAPK14MAPK12MAPK13MAPK11 | |
| SCHEMBL1521661 | 0.79 | KCNJ6 (0.47) | KCNJ6KCNJ5KCNJ3FGFR4MAPK14 | |
| SCHEMBL1521409 | 0.76 | FGFR4 (0.47) | FGFR4BRAFSRC | |
| SCHEMBL1521555 | 0.73 | MAPK14 (0.53) | MAPK14MAPK12MAPK13MAPK11BRAF | |
| SCHEMBL6620598 | 0.73 | FGFR4 (0.71) | FGFR4 | |
| SCHEMBL1521968 | 0.73 | KCNJ6 (0.45) | KCNJ6KCNJ5KCNJ3MAPK14MAPK12 | |
| SCHEMBL1521723 | 0.73 | FGFR4 (0.66) | FGFR4NTRK1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | KCNJ6 990/4885KCNJ5 1019/4885KCNJ3 1035/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | KCNJ6 990/4885KCNJ5 1019/4885KCNJ3 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.